



# Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection

Haripal Kashyap<sup>1</sup> · R. N. Seshendra Kumar<sup>1</sup> · Srishti Gautam<sup>1</sup> · Arvind Gupta<sup>1</sup> · Swati Gupta<sup>1</sup> · Prashant K. Tiwari<sup>1</sup>

Received: 25 February 2021 / Accepted: 27 May 2021 / Published online: 16 July 2021  
© Dr. K C Chaudhuri Foundation 2021

*To the Editor:* Multisystem inflammatory syndrome–children (MIS-C) is a newly recognized spectrum of disease manifestations in children associated with COVID-19 infection [1]. This letter aims to describe the clinicotherapeutic profile of MIS-C COVID-19 cases admitted at a tertiary hospital in Delhi-NCR. We observed 12 cases with a median age of 6.5 y (9 male; 3 female). Eleven showed seropositivity for COVID-19 while 1 had a positive COVID-19 RT-PCR. As proposed by Gupta et al. [2], cases were divided into 3 groups: febrile inflammatory state (5 cases), Kawasaki-like illness (3 cases), and toxic shock syndrome-like classical MIS-C (4 cases). Fever was present in all cases. Gastrointestinal system was the most commonly affected system with vomiting being the most common symptom. Cardiovascular symptoms were seen in 6 (50%) cases. Three children showed neurological impairment with 1 case each of refractory status epilepticus, acute disseminated encephalomyelitis (ADEM), and necrotizing encephalopathy. Respiratory system was involved in 5 (41.6%) children. Elevated CRP was noted in all children, elevated ferritin in 8 (66.7%), elevated D-dimer in 10 (83.3%), and deranged PT/INR/aPTT in 4 (33%) cases. High Pro-BNP was seen in 8; of which, 4 showed deranged ejection fraction. Consolidation and/or pleural effusion was seen in 7 (58.3%) cases. All children received steroids, while 7 children received IVIg. LMWH and aspirin were given to children with raised D-dimer and Kawasaki-like illness, respectively. Six children needed vasopressor support. Three patients died during the course of the disease while 1

suffered morbidity in the form of hemiparesis. Rest all were discharged after full recovery of presenting symptoms.

MIS-C COVID-19 should be considered in cases with longstanding fever and/or multisystem involvement. In the absence of standardized guidelines, clinicians are often missing mild cases or misdiagnosing the presentation [3]. It also emphasizes the need for further studies in this field.

## Declarations

**Conflict of Interest** None.

## References

1. Health advisory on multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019. In: Centers for Disease Control and Prevention (CDC). 2019. Available at [https://emergency.cdc.gov/han/2020/han00432.asp?deliveryNameUSCDC\\_511-DM28431](https://emergency.cdc.gov/han/2020/han00432.asp?deliveryNameUSCDC_511-DM28431). Accessed on 1 Feb 2021.
2. Gupta D, Simalti A, Gupta N, Bhardwaj P, Bansal A, Sachdev A. Management principles of COVID-19 in Adolescents and Children. *Indian J Adolesc Med (Special Section)*. 2020;1:47–57.
3. Levin M. Childhood multisystem inflammatory syndrome—a new challenge in the pandemic. *N Engl J Med*. 2020;383:393–5.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ R. N. Seshendra Kumar  
seshurayasam@gmail.com

<sup>1</sup> Department of Pediatrics, Asian Institute of Medical Sciences Faridabad, Haryana 121001, India